Artivion (AORT)
Builds devices, sealants, valves, and preservation services for cardiac and vascular surgery.
Something off on this page? Send us feedback.
Sells aortic stent grafts, On-X mechanical valves, surgical sealants, and cryopreserved human tissues through medical-device and preservation-services segments. The business is global, but execution centers on surgeon adoption, regulatory approvals, and recently acquired arch-repair systems.
Combines aortic stent grafts, On-X mechanical valves, BioGlue surgical sealants, and cryopreserved cardiac and vascular allografts. Medical Devices is the larger segment, while Preservation Services keeps the CryoLife tissue base inside the portfolio.
Sells through an international network with manufacturing and operating sites in Georgia, Texas, and Germany. The product mix has shifted toward acquired aortic repair platforms, including JOTEC grafts, Ascyrus AMDS, and Endospan's NEXUS system.
Execution depends on surgeon adoption, quality-controlled tissue processing, approvals for specialized cardiovascular devices, and competition from larger device makers. Recent arch-repair additions make commercialization of NEXUS, AMDS, and ARCEVO LSA a structural dependency.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 18, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $39 | Target: $40 |
| Aug 7, 2026 | Canaccord Genuity | Target | Target: $36 | Target: $39 |
| Jun 16, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $51 | Target: $36 |
| Jun 1, 2026 | Stifel Nicolaus | Target | Target: $55 | Target: $45 |
| Apr 10, 2026 | Ladenburg Thalmann | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $77.3M · Total debt $408.0M · Total assets $1.07B · Shareholders' equity $445.6M
- Revenue
- $125.8M
- Operating income
- −$8.4M
- Net income
- −$13.5M
No dividends on record.
| Insiders | 5.09% | 2.47M shares | |
|---|---|---|---|
| 15 holders · as of Sep 11, 2026 | |||
| Strategic holders | 22.41% | 10.88M shares | |
| 3 holders · as of Feb 17, 2026 | |||
| Other | 72.50% | 35.19M shares | |
| remainder | |||
48.54M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Strategic | 12.31% | 5.98M | filed Oct 17, 2025 |
Wasatch Advisors, Inc.Institution | 5.74% | 2.79M | filed Feb 11, 2022 |
Nomura Asset Management International Inc.Strategic | 5.38% | 2.61M | filed Feb 17, 2026 |
FMR LLCStrategic | 4.71% | 2.29M | filed Aug 6, 2025 |
SMALLCAP World Fund, Inc.Institution | 4.05% | 1.96M | filed Feb 14, 2019 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Andrew M. Green | officer: SVP, Regulatory and Quality | −11,480 | $24.97 |
| Sep 3, 2026 | Andrew M. Green | officer: SVP, Regulatory and Quality | −1,493 | $26.02 |
| Sep 2, 2026 | Andrew M. Green | officer: SVP, Regulatory and Quality | −6,510 | $27.27 |
| Aug 19, 2026 | James P. Mackin | officer: President & CEO | −70,000 | $28.96 |
| Aug 14, 2026 | Lance A. Berry | officer: EVP, COO, CFO & Treasurer | −715 | $28.55 |
- Medtronic
Broad overlap in aortic stent grafts and surgical valves
- Edwards Lifesciences
Structural-heart rival in surgical valves, conduits, and patches
- Abbott
Mechanical and tissue valve competitor in cardiac surgery
- BD
Vascular sealant overlap in aortic and vascular surgery
- Baxter International
Adjunctive hemostat and cardiovascular sealant competitor
- LeMaitre
Vascular patch and reconstruction competitor
- Elutia
Cardiovascular biomatrix and tissue-repair competitor
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Artivion | $24.13 | −0.04% | $1.15B | — | 73.1 | 2.4 | +11.3% |
| Medtronic | $90.80 | +0.03% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Edwards Lifesciences | $88.78 | −0.02% | $50.87B | 50.8 | 28.3 | 7.8 | +13.6% |
| Abbott | $104.00 | +0.27% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| BD | $183.00 | −0.03% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Baxter International | $23.73 | +0.23% | $11.85B | — | 11.2 | 1.0 | +5.3% |
| LeMaitre | $80.98 | 0.00% | $1.81B | 27.8 | 26.5 | 6.9 | +9.6% |
| Elutia | $0.8102 | 0.00% | $37.7M | 0.9 | — | 3.1 | −61.3% |
| Median | 30.5 | 16.5 | 3.1 | +9.6% |